Compare Davita Inc (DVA) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs EPAM Systems Inc — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while EPAM Systems Inc trades at $99.9 (market cap $5.02B). The key difference: Davita Inc is far larger — about 2.3× EPAM Systems Inc's market cap, and Davita Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| DVA | EPAM | |
|---|---|---|
Market Cap | $11.72B | $5.02B |
Sector | Health | Technology |
52-Week High | $240.96 | $221.40 |
52-Week Low | $103.87 | $76.04 |
Enterprise Value | $24.44B | $4.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
EPAM Systems trades at $97.43, up 4.68% today, but faces bearish technical signals with resistance at $99. The company delivered strong Q2 2026 earnings beats with EPS of $3.38 versus $3.16 expected, though revenue guidance was lowered due to slower North American growth. Valuation metrics appear attractive with P/E of 13.22 and P/S of 0.94, while profitability remains solid with 7.15% net margin.
Despite near-term headwinds, EPAM's partnership with OpenAI and strong AI-native revenue growth provide long-term catalysts. Risks include software services demand softness and competitive pressures. Analyst consensus remains bullish with $117.27 price target (20% upside), though investors should monitor execution against revised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
